Catalyst Discusses Vigabatrin Results

Vigabatrin has proven effective in helping subjects abstain from cocaine usage in a Phase II study by Catalyst Pharmaceutical Partners.

 

Catalyst’s CPP-109 is bioequivalent to vigabatrin.

The 103-subject, randomized, double-blind, placebo-controlled trial showed more subjects treated with vigabatrin were able to abstain from cocaine usage during the last three weeks of the dosing period compared with those receiving placebo, Catalyst said.